Diagnosis and monitoring of liver disease

A method for characterizing liver disease, the method comprising:

• detecting, in a sample from a subject, a quantity of each of a plurality of distinct reporters that are released from activity sensors, wherein different members of the plurality of reporters are released by proteases that are differentially active in diseased liver tissue versus healthy liver tissue, the proteases comprising at least 4 different proteases selected from the group consisting of FAP, MMP2, ADAMTS2, FURIN, MMP14, GZMB, PRSS8, MMP8, ADAM 12, CTSS, CTSA, CTSZ, CASP1, ADAMTS12, CTSD, CTSW, MMP11, MMP12, GZMA, MMP23B, MMP7, ST14, MMP9, MMP15, ADAMDEC1, ADAMTS1, GZMK, KLK11, MMP19, PAPPA, CTSE, PCSK5, and PLAU;
• determining and classifying that the subject has nonalcoholic steatohepatitis (NASH) at one of stages NASH F1, NASH F2, NASH F3, or NASH F4, based upon relative quantities of the detected reporters, thereby characterizing the disease.